PEPFAR Data Finally Released: Officials Claim Victory While Health Experts Sound the Alarm

Long-Awaited PEPFAR Data Sparks Sharp Divide Between Officials and Health Experts

For months, global health professionals around the world have been anxiously waiting. Now, the data they sought has finally arrived — and it has ignited a fierce debate about the true state of America's flagship HIV/AIDS program.

The State Department released new figures on PEPFAR — the President's Emergency Plan for AIDS Relief — late on a Friday afternoon, ending a prolonged period of silence that had left researchers, advocates, and policymakers in the dark. The release marks the first official data update since President Trump returned to office in January 2025.

What Is PEPFAR and Why Does It Matter?

Launched in 2003 under President George W. Bush, PEPFAR has become one of the most celebrated public health initiatives in modern history. The program funds HIV diagnosis, treatment, outreach, and support services across 50 countries, and is widely credited with saving an estimated 26 million lives. The United States currently invests approximately $5 billion annually to sustain these efforts.

The central question hanging over the program this year has been straightforward but deeply consequential: when the Trump administration moved to freeze foreign aid in early 2025, how badly did that disruption damage PEPFAR's life-saving operations? And did emergency waivers — designed to shield critical programs from the cuts — succeed in softening the blow?

The Government's Position: Programs Proved Resilient

According to Trump administration officials, the numbers tell an encouraging story.

"The numbers are very, very good," said Jeremy Lewin, acting undersecretary of state for foreign assistance, humanitarian affairs and religious freedom, speaking at a public event. "People will be surprised at, I think, how resilient our health programs are and have been."

Officials were particularly eager to highlight progress on one of the administration's stated priorities: eliminating mother-to-child HIV transmission. Data showed that the number of pregnant and breastfeeding women beginning PrEP — a medication that prevents HIV contraction — more than doubled, rising from 43,000 in the final quarter of 2024 to 103,000 in the final quarter of 2025.

The State Department also pointed out that the U.S. continued to support HIV treatment for more than 20 million people across 50 countries as of late September 2025 — a figure only marginally lower than the previous year's total.

In a follow-up media note, the department stated plainly: "We cut overall spending by 30 percent while preserving critical frontline HIV care and eliminating wasteful programs. This proves the America First Global Health Strategy works."

Health Experts and Advocates Tell a Very Different Story

Outside experts who rapidly analyzed the same dataset reached starkly different conclusions — and many are raising urgent alarms.

"These data show nothing less than a five-alarm fire," said Asia Russell, executive director of the advocacy organization Health GAP. She pointed to sharp declines in HIV testing, prevention services, and community support programs as evidence of serious structural damage to the program.

The Foundation for AIDS Research, known as amfAR, conducted its own assessment in collaboration with experts from the International AIDS Society. The organizations concluded that the data reveals "substantial disruptions across PEPFAR service areas" that represent "a troubling inflection point" for the program's future.

Treatment Numbers: A Historic Decline

Brian Honermann, deputy director of public policy at amfAR, argued that the State Department's framing of the data "obscures the true damage of the interruptions."

While acknowledging that the treatment figures were better than some worst-case predictions, Russell was unsparing in her assessment. "For the first time in history, PEPFAR has put fewer people on HIV therapy than the year before. That is an absolute indictment of this administration," she said.

The Collapse of Frontline Support Infrastructure

Honermann emphasized that the damage extends well beyond treatment numbers. Approximately 24% of frontline healthcare workers previously supported by PEPFAR funding are no longer in their roles. These workers were casualties of program cancellations affecting services not classified as directly life-saving — including community health workers who made home visits to monitor patients, and peer-support group facilitators who worked with HIV-positive teenagers.

The impact of losing that support network is already visible in the data. In PEPFAR-funded clinics where services continued without interruption, new HIV diagnoses declined by 13%. In locations where services were temporarily halted due to the aid freeze, diagnoses dropped by nearly 30%.

"That's hundreds of thousands of people that we would have expected to see get their diagnoses and get put under treatment — and those people are now just missing," Honermann said. "That's bad for their own health and well-being, and it also allows the space for HIV to continue to spread."

A Legacy of Transparency Now Under Question

Beyond the raw numbers, experts expressed concern about what the delayed release and selective presentation of data says about PEPFAR's commitment to accountability.

In past years, PEPFAR published performance data on a quarterly basis — four releases per year — giving researchers and policymakers a continuous, granular view of program performance. That consistency was considered a hallmark of the program's credibility.

"PEPFAR has been the most transparent and effective global health program of the past 25 years," said Honermann. He credited the program's data infrastructure as central to its success, noting that its metrics were "specifically honed to be ambitious but also to hold itself accountable."

The year-long gap in reporting, combined with what critics describe as a carefully curated data release, has raised questions about whether that tradition of transparency remains intact.

What Comes Next

As global health organizations continue to dig into the newly released figures, the debate over PEPFAR's trajectory is unlikely to quiet down. For advocates, the numbers represent a warning that cannot be dismissed. For the Trump administration, they serve as evidence that strategic cuts can coexist with continued progress.

What is beyond dispute is that millions of lives hang in the balance — and the decisions made about PEPFAR's funding and focus in the coming months will have consequences that stretch far beyond any government press release.